Innoviva (INVA) EBT (2010 - 2026)
Innoviva's (INVA) quarterly EBT came in at $234.6 million in Q1 2026, up 707.85% YoY from $29.0 million in Q1 2025, and up 1472.36% on a QoQ basis from -$17.1 million in Q4 2025.
Innoviva (INVA) EBT (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of EBT data on file, last reported at $234.6 million in Q1 2026.
- Quarterly EBT rose 707.85% year-over-year to $234.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $421.9 million (up 260.2% YoY) and the FY2025 annual result came in at $326.9 million, up 1257061.54% from the prior year.
- EBT advanced to $234.6 million in Q1 2026, from -$17.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of $351.6 million in Q3 2022 to a low of -$198.2 million in Q4 2024.
- A 5-year average of $45.5 million and a median of $20.5 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2024 — EBT slumped 1847.08% — and 2025, when it surged 938.49%.
- Tracing INVA's EBT over 5 years: stood at -$15.9 million in 2022, then jumped by 36.0% to -$10.2 million in 2023, then tumbled by 1847.08% to -$198.2 million in 2024, then surged by 91.38% to -$17.1 million in 2025, then surged by 1472.36% to $234.6 million in 2026.
- The last three EBT figures came in at $234.6 million (Q1 2026), -$17.1 million (Q4 2025), and $131.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | -108.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -108.02 Mn |
| Mar 31, 2026 | 234.56 Mn |
| Dec 31, 2025 | -17.09 Mn |
| Sep 30, 2025 | 131.83 Mn |
| Jun 30, 2025 | 72.60 Mn |
| Mar 31, 2025 | -38.59 Mn |
| Dec 31, 2024 | -198.17 Mn |
| Sep 30, 2024 | 12.69 Mn |
| Jun 30, 2024 | -39.28 Mn |
| Mar 31, 2024 | 45.12 Mn |
| Dec 31, 2023 | -10.18 Mn |
| Sep 30, 2023 | 132.90 Mn |
| Jun 30, 2023 | 5.81 Mn |
| Mar 31, 2023 | 41.14 Mn |
| Dec 31, 2022 | -15.90 Mn |
| Sep 30, 2022 | 351.64 Mn |
| Jun 30, 2022 | 20.50 Mn |
| Mar 31, 2022 | 44.72 Mn |
| Dec 31, 2021 | -44.88 Mn |
| Sep 30, 2021 | 388.79 Mn |